Newsfeed
Real-time intelligence on synbio and synbio funding, regulatory milestones, deployments, and policy.
MUC16 CAR-T Cuts Bladder Tumor Growth via Catheter
MUC16-targeting CAR T cells delivered via catheter controlled bladder tumors in mice, opening a local delivery route for solid tumor CAR-T.
Read →Serapha Raises $230M Around China Gene-Editing Asset
Serapha closes $230M debut round built around a Chinese-originated gene-editing candidate, one of 2026's largest synbio therapy raises.
Read →AI Designs Caffeine-Based Molecular Switch for Cell Control
Researchers use AI to engineer caffeine as a reversible off-switch for gene circuits and CAR-T cells
Read →TRIM Platform Stacks 3+ Crop Traits via Twin Prime Editing
New genome engineering platform combines prime editing with knockouts for efficient multi-trait crop development
Read →D&D-seq Maps DNA-Protein Contacts at Single-Cell Resolution
New method uses base editor-nanobody fusions to record DNA-protein interactions in individual cells
Read →NTLA Surges 35% on Phase 3 Gene Editing Readout Anticipation
NTLA jumps 35% overnight as investors position ahead of first Phase 3 CRISPR therapy data expected this quarter
Read →Lilly Licenses Ascidian Gene Editing Tech for Kidney Disease
Eli Lilly secures exclusive licensing deal with Ascidian for gene editing platform targeting kidney diseases
Read →Lundbeck Partners with Cradle for AI Protein Design Platform
Danish pharma giant Lundbeck teams with AI protein design startup Cradle to accelerate drug discovery programs
Read →YolTech Raises $70M Series B for CRISPR Therapies in China
Chinese gene editing startup secures major funding to advance CRISPR therapeutic pipeline
Read →PRINCE System Enables Reversible Gene Editing with Small Molecules
New CRISPR system allows researchers to turn gene editing on and off with small molecules
Read →Off-Shelf Gene Editing Shows 85% Efficacy in Sickle Cell Primates
Primate study demonstrates 85% editing efficiency using allogeneic approach, potentially eliminating patient-specific manufacturing
Read →Precision BioSciences Misses Q1 Earnings Amid Gene Editing Volatility
DTIL platform company reports revenue shortfall as gene editing sector faces investor skepticism
Read →RNA Motifs Boost Prime Editing Efficiency 4x in New Study
Engineered RNA-stabilizing motifs quadruple prime editing success rates through directed evolution approach
Read →In Vivo Gene Editing Market Hits $37.75B by 2032
In vivo gene editing market projected to reach $37.75 billion by 2032, driven by CRISPR advances and clinical successes
Read →Precision BioSciences ECUR-506 Trial Data Sparks Investor Interest
Precision BioSciences gains attention following new ECUR-506 trial data, highlighting ARCUS platform capabilities in allogeneic CAR-T
Read →MD Anderson CAR-T Therapy Enters Phase I for Solid Tumors
UT MD Anderson's novel CAR-T approach targets solid tumor challenges with enhanced persistence and trafficking capabilities.
Read →Editas EDIT-401 Achieves 90% LDL-C Reduction in 6-Month NHP Study
Single-dose base editor achieves sustained cholesterol reduction in non-human primates with 6-month durability data
Read →Melazyme Raises $2M for Melanin and Sweet Proteins
Perfect Day alumni launch Melazyme with $2M seed round targeting melanin biosynthesis and alternative sweetener production
Read →Pichia Pastoris Cell-Free System Cuts Protein Production Costs
New yeast-based cell-free expression system promises significant cost reductions for therapeutic protein manufacturing
Read →Gene Editing Extends Epilepsy Mouse Survival by 400%
CRISPR correction of SCN1A mutations dramatically improves survival in Dravet syndrome mouse model
Read →